Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

141. Apixaban reduced stroke or systemic embolism more than warfarin in AF regardless of renal function. (PubMed)

Apixaban reduced stroke or systemic embolism more than warfarin in AF regardless of renal function. 23247956 2013 04 12 2012 12 18 1539-3704 157 12 2012 Dec 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Apixaban reduced stroke or systemic embolism more than warfarin in AF regardless of renal function. JC6-7 10.7326/0003-4819-157-12-201212180-02007 Jones Melvyn M MM University College London Medical School, London, England, UK. eng Comment Journal Article United States Ann

2012 Annals of Internal Medicine

142. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis (PubMed)

A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis Animal and human studies support the importance of the coagulation cascade in pulmonary fibrosis.In a cohort of subjects with progressive idiopathic pulmonary fibrosis (IPF), we tested the hypothesis that treatment with warfarin at recognized therapeutic doses would reduce rates of mortality, hospitalization, and declines in FVC.This was a double-blind, randomized, placebo-controlled trial of warfarin targeting (...) an international normalized ratio of 2.0 to 3.0 in patients with IPF. Subjects were randomized in a 1:1 ratio to warfarin or matching placebo for a planned treatment period of 48 weeks. International normalized ratios were monitored using encrypted home point-of-care devices that allowed blinding of study therapy.The primary outcome measure was the composite outcome of time to death, hospitalization (nonbleeding, nonelective), or a 10% or greater absolute decline in FVC. Due to a low probability of benefit

Full Text available with Trip Pro

2012 EvidenceUpdates

143. Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism

Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism Management Briefs Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs Health Services Research & Development Management Briefs Management eBriefs: Provide VA senior managers with results from VA Health Services Research in a concise

2012 Veterans Affairs - R&D

144. Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis

Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

145. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review

Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

146. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. (PubMed)

Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. The need for anticoagulation after surgical aortic valve replacement (AVR) with biological prostheses is not well examined.To perform a nationwide study of the association of warfarin treatment with the risk of thromboembolic complications, bleeding incidents, and cardiovascular deaths after bioprosthetic AVR surgery.Through a search (...) in the Danish National Patient Registry, 4075 patients were identified who had bioprosthetic AVR surgery performed between January 1, 1997, and December 31, 2009. Concomitant comorbidity and medication were retrieved. Poisson regression models were used to determine risk.Incidence rate ratios (IRRs) of strokes, thromboembolic events, cardiovascular deaths, and bleeding incidents by discontinuing warfarin as opposed to continued treatment 30 to 89 days, 90 to 179 days, 180 to 364 days, 365 to 729 days

Full Text available with Trip Pro

2012 JAMA

147. Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial (PubMed)

Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial To evaluate the impact of a pharmacist-led warfarin patient self-management program on quality of life and anticoagulation control compared with management in a physician-led specialized anticoagulation clinic.Prospective, randomized, controlled, open-label trial.Tertiary care academic medical center.A total of 114 patients aged 18-75 years who were followed (...) at a specialized anticoagulation clinic, had received warfarin for at least 6 months, and were expected to continue warfarin for a minimum of 4 months.All patients attended an educational session on anticoagulation provided by a pharmacist. Patients randomized to the self-management group (58 patients) also received practical training to use the CoaguChek XS device and a self-management dosing algorithm. Patients in the control group (56 patients) continued to undergo standard management at the anticoagulation

2012 EvidenceUpdates

148. Meta-Analysis of Safety and Efficacy of Uninterrupted Warfarin Compared to Heparin-Based Bridging Therapy During Implantation of Cardiac Rhythm Devices (PubMed)

Meta-Analysis of Safety and Efficacy of Uninterrupted Warfarin Compared to Heparin-Based Bridging Therapy During Implantation of Cardiac Rhythm Devices Optimal management of perioperative anticoagulation in patients undergoing pacemaker or implantable cardioverter-defibrillator implantation is not yet established. We performed a meta-analysis of the published literature to assess the safety and efficacy of perioperative heparin-based bridging therapy versus uninterrupted warfarin therapy (...) in patients undergoing pacemaker or implantable cardioverter-defibrillator implantation. We performed a systematic review of MEDLINE (1950 to 2012), EMBASE (1988 to 2012), Cochrane Controlled Trials Register (fourth quarter 2011), and reports presented at scientific meetings (1994 to 2011). Randomized controlled trials, case-control, or cohort studies comparing the safety and efficacy of uninterrupted warfarin therapy to heparin-based bridging therapy were eligible. Outcomes reported in eligible studies

2012 EvidenceUpdates

149. Optimal warfarin management for the prevention of thromboembolic events in patients with atrial fibrillation: a systematic review of the clinical evidence. (PubMed)

Optimal warfarin management for the prevention of thromboembolic events in patients with atrial fibrillation: a systematic review of the clinical evidence. 23002382 2012 09 25 2018 11 13 1481-4501 2 3 2012 CADTH technology overviews CADTH Technol Overv Optimal warfarin management for the prevention of thromboembolic events in patients with atrial fibrillation: a systematic review of the clinical evidence. e2304 eng Journal Article 2012 09 01 Canada CADTH Technol Overv 101566385 1203-9012 2012 9

Full Text available with Trip Pro

2012 CADTH technology overviews

150. Review: New oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF. (PubMed)

Review: New oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF. 22986394 2012 12 03 2012 09 18 1539-3704 157 6 2012 Sep 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Review: new oral anticoagulants reduced stroke and systemic embolism compared with warfarin in AF. JC3-2 10.7326/0003-4819-157-6-201209180-02002 Klein Liviu L eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819 Am J Cardiol. 2012 Aug 1;110(3):453-60

2012 Annals of Internal Medicine

151. Warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. (PubMed)

Warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. 22910961 2012 10 19 2012 08 22 1539-3704 157 4 2012 Aug 21 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: warfarin and aspirin did not differ for death or stroke in heart failure and sinus rhythm. JC2-7 10.7326/0003-4819-157-4-201208210-02007 Ahmad Tariq T Duke University School of Medicine, Durham, North Carolina, USA. Felker G Michael GM eng Comment Journal Article United States Ann

2012 Annals of Internal Medicine

152. Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial (PubMed)

Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required.The current analysis was undertaken to compare the periprocedural bleeding risk of patients in the Randomized (...) Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial treated with dabigatran and warfarin. Bleeding rates were evaluated from 7 days before until 30 days after invasive procedures, considering only the first procedure for each patient. A total of 4591 patients underwent at least 1 invasive procedure: 24.7% of patients received dabigatran 110 mg, 25.4% received dabigatran 150 mg, and 25.9% received warfarin, P=0.34. Procedures included: pacemaker/defibrillator insertion (10.3%), dental procedures

Full Text available with Trip Pro

2012 EvidenceUpdates

153. INR Online Software for the Management of Warfarin Dosing in Patients Requiring Warfarin Treatment: Clinical Evidence

INR Online Software for the Management of Warfarin Dosing in Patients Requiring Warfarin Treatment: Clinical Evidence Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within (...) for the Management of Warfarin Dosing in Patients Requiring Warfarin Treatment: Clinical Evidence DATE: 8 August 2012 RESEARCH QUESTION What is the clinical evidence regarding the use of the INR Online Software, in conjunction with point of care testing, for the management of international normalized ratio dosing in patients requiring warfarin treatment? KEY MESSAGE No relevant information was identified regarding the INR Online Software, in conjunction with point of care testing, for the management

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

154. Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism

Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism Evidence-based Synthesis Program Department of Veterans Affairs Health Services Research & Development Service April 2012 Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism Prepared for: Department of Veterans Affairs Veterans Health Administration (...) . Warfarin and Newer Oral Anticoagulants: Long-term Prevention and Treatment of Arterial and VTE Evidence-based Synthesis Program PREFACE Quality Enhancement Research Initiative’s (QUERI’s) Evidence-based Synthesis Program (ESP) was established to provide timely and accurate syntheses of targeted healthcare topics of particular importance to Veterans Affairs (V A) managers and policymakers, as they work to improve the health and healthcare of Veterans. The ESP disseminates these reports throughout V

2012 Veterans Affairs Evidence-based Synthesis Program Reports

155. Warfarin in Heart Failure. (PubMed)

Warfarin in Heart Failure. 22551103 2012 05 24 2018 12 01 1533-4406 366 20 2012 May 17 The New England journal of medicine N. Engl. J. Med. Warfarin in heart failure. 1936-8 10.1056/NEJMe1202504 Eikelboom John W JW Connolly Stuart J SJ eng Editorial Comment 2012 05 02 United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Platelet Aggregation Inhibitors 5Q7ZVV76EI Warfarin R16CO5Y76E Aspirin AIM IM N Engl J Med. 2012 May 17;366(20):1859-69 22551105 Anticoagulants therapeutic use (...) Aspirin therapeutic use Female Heart Failure drug therapy Humans Male Platelet Aggregation Inhibitors therapeutic use Warfarin therapeutic use 2012 5 4 6 0 2012 5 4 6 0 2012 5 25 6 0 ppublish 22551103 10.1056/NEJMe1202504

2012 NEJM

156. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis

Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

157. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses Pink J, Lane S, Pirmohamed M, Hughes DA Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of dabigatran etexilate and warfarin in patients with non-valvular atrial fibrillation and a moderate-to-high risk of stroke. Dabigatran 110mg

2012 NHS Economic Evaluation Database.

158. A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children

A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2012 PedsCCM Evidence-Based Journal Club

159. ARISTOTLE: Apixaban vs Warfarin in patients with Atrial Fibrillation

ARISTOTLE: Apixaban vs Warfarin in patients with Atrial Fibrillation RXFILES TRIAL SUMMARY ORIGINALLY PREPARED BY: M JIN, REVISED BY: L KOSAR – UPDATED NOV 2012 – WWW.RXFILES.CA Page 1 of 3 ARISTOTLE: Apixaban vs Warfarin in patients with Atrial Fibrillation 1 Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation BOTTOM LINE In atrial fibrillation (AF) patients with an ? risk of stroke (mean CHADS 2 score 2.1): • Apixaban 5mg po BID was superior to warfarin (...) for ? stroke or systemic embolism (NNT=167/1.8 years) • Apixaban, compared to warfarin, had: - ? stroke (NNT=175/1.8yr), hemorrhagic stroke (NNT=238/1.8yr) & mortality (NNT=132/1.8yr) - ? bleeding major (NNT=67/1.8yr), intracranial (NNT=128/1.8yr), other & any bleeding & ? discontinuation rates (NNT=45/1.8yr) • Net clinical benefit stroke, systemic embolism, major bleeding or death from any cause favours apixaban over warfarin (NNT=56/1.8 years) • At time of publication, apixaban is not approved by Health

2012 RxFiles

160. ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation

ROCKET?AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation RXFILES TRIAL SUMMARY ORIGINALLY PREPARED BY: M JIN, REVISED BY: L KOSAR – UPDATED DECEMBER 2012 – WWW.RXFILES.CA Page 1 of 4 ROCKET-AF: Rivaroxaban vs Warfarin in patients with Atrial Fibrillation 1 Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in AF BOTTOM LINE In atrial fibrillation (AF) patients with an ? risk of stroke (mean CHADS (...) 2 score 3.5), rivaroxaban 20mg po daily: ? Was non-inferior (i.e. no worse than) to warfarin for ? stroke or systemic embolism ? Had less hemorrhagic strokes, systemic embolism & bleeding (critical, fatal & intracranial) versus warfarin ? Had more drops in hemoglobin =20 g/L, tranfusions, gastrointestinal bleeding, epistaxis & hematuria versus warfarin ? At time of publication, rivaroxaban for AF is approximately $100/month; 15mg, 20mg tablets. ? A Fib, ? Warfarin + monitoring ~$35/month

2012 RxFiles